Kulkarni Inducted into American Institute for Medical and Biological Engineering

Content

Ashish Kulkarni, associate professor and Edward S. Price Faculty Fellow of chemical and biomolecular engineering in the Riccio College of Engineering, has been inducted into the 2026 class of the College of Fellows for the American Institute for Medical and Biological Engineering (AIMBE).  

Among the highest professional distinctions accorded to medical and biological engineers, membership in the AIMBE College of Fellows honors those who have made outstanding contributions to engineering and medicine research, practice, or education and to the pioneering of new and developing fields of technology, making major advancements in traditional fields of medical and biological engineering or developing/implementing innovative approaches to bioengineering education. AIMBE Fellows represent more than 35 countries and are employed in academia, industry, clinical practice and government, and those elected represent the top 2% of engineers in their respective fields.

Kulkarni was accepted into the College of Fellows “in recognition of pioneering contributions to immunoengineering, drug delivery and cancer therapy, and for development of computationally designed nanomaterials,” according to AIMBE.

Within the last few years, Kulkarni has received the inaugural Glass Family Faculty Innovation Fellowship to develop a sprayable psoriasis treatment, the AIChE Langer Prize for Innovation and Entrepreneurial Excellence for detecting ovarian cancer, and an Institute of Diversity Sciences seed grant to develop strategies to bypass cancer’s multidrug resistance. He was elected as a senior member of the National Academy of Inventors (NAI) and selected as a UMass Amherst Spotlight Scholar. He has co-founded two start-up companies based on his cancer treatment and diagnostic research. 

“I am deeply honored by this recognition from AIMBE, which reflects the outstanding efforts of the students and trainees in my lab and our shared commitment to advancing engineering-driven therapeutic and diagnostic approaches for cancer,” Kulkarni says.

This story was first published by the UMass News Office.